Total cancer care moffit cancer center
GO
 

Kenneth S. Zuckerman, MD

Where You Are:
Kenneth S. Zuckerman, MD

Senior Member

Office  (813) 745-8090

Education And Training
  • Fellow, Harvard Medical School and Peter Bent Brigham Hospital, 1978 - Hematology
  • Resident, Ohio State University Hospital, 1975 - Internal Medicine
  • Intern, Ohio State University Hospital, 1973 - Internal Medicine
  • MD, Ohio State University Medical School, 1972


  • Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg Med Chem Lett. 2009 Sep;19(13):3598-3601. Pubmedid: 19447617. Pmcid: PMC2812898.
  • Montenegro DE, Franklin T, Moscinski LC, Zuckerman KS, Hu XT. TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k). Cell Prolif. 2009 Feb;42(1):1-9. Pubmedid: 19143758.
  • Wolvetang E, Pera M, Zuckerman K. Gap junction mediated transport of shRNA between human embryonic stem cells. Biochem Biophys Res Commun. 2007 Nov;363(3):610-615. Pubmedid: 17900528.
  • Hu X, Cui D, Moscinski LC, Zhang X, Maccachero V, Zuckerman KS. TGFbeta regulates the expression and activities of G2 checkpoint kinases in human myeloid leukemia cells. Cytokine. 2007 Feb;37(2):155-162. Pubmedid: 17459720.
  • Johnson J, Moscinski L, Zuckerman K. Value of positron emission tomography scan in staging cancers, and an unusual presentation of acute myeloid leukemia. Case 3. Acute myeloid leukemia presenting with lytic bone lesions. J Clin Oncol. 2004;22(14):2968-2970. Pubmedid: 15254066.
  • Crist T, Barr W, Linas S, Zuckerman K. Using local solutions to address a national issue: ASP's recommendations to ensure the vitality of clinical research. Am J Med. 2004;116(5):359-362. Pubmedid: 14984829.
  • Hu X, Bryington M, Fisher AB, Liang X, Zhang X, Cui D, Datta I, Zuckerman KS. Ubigquitin/proteosome-dependent degradation of D-type cyclin is linked to tumor necrosis factor-induced cell cycle arrest. J Biol Chem. 2002 May;277(19):16528-16537. Pubmedid: 11864973.
  • Hu X, Zhang X, Zhong Q, Fisher AB, Bryington M, Zuckerman KS. Differential effects of transforming growth factor on cell cycle regulatory molecules in human myeloid leukemia cells. Oncogene. 2001 Oct;20(47):6840-6850. Pubmedid: 11687963.
  • Hu X, Janssen WE, Moscinski LZC, Bryington M, Dangsupa A, Rezai-Zadeh N, Babbin BA, Zuckerman KS. An IkappaBalpha inhibitor causes leukemia cell death through a p38 MAP kinase-dependent, NF-kappaB-independent mechanism. Cancer Res. 2001 Aug;61(16):6290-6296. Pubmedid: 11507084.
  • Hu X, Zuckerman K. Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J Hematother Stem Cell Res. 2001;10(1):67-74. Pubmedid: 11276360.
  • Liu RY, Fan C, Liu G, Olashaw NE, Zuckerman KS. Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha -supported proliferation of leukemia and lymphoma cell lines. J Biol Chem. 2000 Jul;275(28):21086-21093. Pubmedid: 10783388.
  • Hu X, Zuckerman KS. Cell cycle and transcriptional control of human myeloid leukemic cells by transforming growth factor beta. Leuk Lymphoma. 2000 Jul;38(3-4):235-246. Pubmedid: 10830731.
  • Hu X, Cress, Jr. W, Zhong Q, Zuckerman K. Transforming growth factor beta inhibits the phosphorylation of pRB at multiple serine/threonine sites and differentially regulates the formation of pRB family-E2F complexes in human myeloid leukemia cells. Biochem Biophys Res Commun. 2000;276(3):930-939. Pubmedid: 11027571.
  • Hu X, Moscinski L, Valkov N, Fisher A, Hill R, Zuckerman K. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line. Cell Growth Differ. 2000;11(4):191-200. Pubmedid: 10775036.
  • Hauser R, Friedlander J, Baker M, Thomas J, Zuckerman K. Adult Chediak-Higashi parkinsonian syndrome with dystonia. Mov Disord. 2000;15(4):705-708. Pubmedid: 10928582.
  • Liu RY, Fan C, Garcia R, Jove R, Zuckerman KS. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines. Blood. 1999 Apr;93(7):2369-2379. Pubmedid: 10090948.
  • Hu X, Moscinski LC, Zuckerman KS. Transforming growth factor beta inhibits growth of more differentiated myeloid leukemia cells and retinoblastoma protein phosphorylation at serine 795. Exp Hematol. 1999 Apr;27(4):605-614. Pubmedid: 10210318.
  • Hu X, Tang M, Fisher A, Olashaw N, Zuckerman K. TNF-alpha-induced growth suppression of CD34+ myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-kappa B activation. J Immunol. 1999;163(6):3106-3115. Pubmedid: 10477576.
  • Hu X, Tang M, Fisher A, Olashaw N, Zuckerman K. Tumor necrosis factors alpha (TNFalpha)-induced growth suppression of CD34+ myeloid leukemic cell lines signals through TNF receptor type I and is associated with NF-kB activation. J Immunol. 1999;165:3106-3115. Pubmedid: noPMID.
  • Liu R, Fan C, Olashaw N, Wang X, Zuckerman K. Tumor necrosis factor (TNF)-alpha-induced proliferation of human Mo7e leukemic cells occurs via activation of NF-kB transcription factor. J Biol Chem. 1999;274(20):13877-13885. Pubmedid: 10318796.
  • Liu R, Fan C, Mitchell S, Chen Q, Wu J, Zuckerman K. The role of type I and type II tumor necrosis factor (TNF) receptors in the ability of TNF-alpha to transduce a proliferative signal in the human megakaryoblastic leukemic cell line mo7e. Cancer Res. 1998;58(10):2217-2223. Pubmedid: 9605769.
  • Hu X, Zuckerman K. Cloning and sequencing of an alternative splicing-derived cDNA variant of the GM-CSF receptor alpha subunit, which encodes a truncated protein lacking 397 bp. Am J Hematol. 1998;58:145-147. Pubmedid: 9625584.
  • Hu X, Moscinski L, Hill B, Chen Q, Wu J, Fisher A, Zuckerman K. Characterization of a unique factor-independent variant derived from human factor-dependent TF-1 cells: a transformed event. Leuk Res. 1998;22:817-826. Pubmedid: 9716013.
  • Zuckerman K. Hematopoietic abnormalities in patients with cancer. Cancer Control. 1998;5:6-9. Pubmedid: 10762460.
  • Hu X, Zuckerman K. Removing monolayer cells from culture dishes by incubation with EDTA in studies of cell structure receptors. Biotechniques. 1996;21(5):784-786. Pubmedid: 8922612.
  • Hu X, Moscinski L, Hill B, Zuckerman K. 1996;3353.
  • Hu X, Zuckerman K. Isolation and expression of three mRNA alternative splicing-derived variants encoding the alpha subunit of the human GM-CSF receptor (a). Blood. 1995;86:1240-1240. Pubmedid: noPMID.
  • Busque L, Gilliand D, Prchal J, Sieff C, Weinstein H, Sokol J, Belickova N, Wayne A, Zuckerman K, Sokol L, Castelberry R, Emanuel P. Clonality in juvenile chronic myelogenous leukemia. Blood. 1995;85:21-30. Pubmedid: 7803795.
  • Hu X, Zuckerman K. Isolation of full-length cDNA clones encoding the common (beta)-subunit of the GM-CSF, IL-3, and IL-5 receptors by RT-PCR. Focus. 1995;17(1):21-24. Pubmedid: noPMID.
  • Saba H, Nawab U, Nadeem S, Cosgrove D, Moscinski L, Spiers A, Balducci L, Lyman G, Zuckerman K. 1994;624a.
  • Zuckerman K. Efficacy of intensive, high dose anthracycline-based therapy in intermediate-and high-grade non-Hodgkin's lymphomas. Semin Oncol. 1994;21:59-64.
  • Hu X, Emanuel P, Zuckerman K. Cloning and sequencing of the cDNAs encoding two alternative splicing-derived variants of the alpha-subunit of the granulocyte-macrophage colony-stimulating factor receptor. Biochem Biophys Acta. 1994;1223:306-308.
  • Castleberry R, Emanuel P, Zuckerman K, Cohn S, Strauss L, Byrd R, Homans A, Chaffee S, Nitschke R, Gualtieri R. A pilot study of 13-cis-retinoic acid in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med. 1994;331:1680-1684.
  • Hu X, Zuckerman K. 1993;77a.
  • Zuckerman K, Case D, Gams R, Prasthofer E. Chemotherapy of intermediate and high-grade non-Hodgkin's lymphomas with an intensive high-dose epirubicin-containing regimen (EVDAC). Blood. 1993;82:3564-3573.
  • Zuckerman K. Myeloproliferative disorders. Curr Opin Hematol. 1993;1:189-194.
  • Zuckerman K. Myelodysplasia. Curr Opin Hematol. 1993;1:183-188.
  • Zuckerman K. Hematopoietic growth factors in the treatment of myelodysplastic syndromes. Biotherapy Rep. 1992;2:1-7.
  • Wagner J, Broxmeyer H, Byrd R, Zehnbauer B, Schmeckpeper B, Shah N, Griffin C, Emanuel P, Zuckerman K, Cooper S, Carow C, Bias W, Santos G. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood. 1992;79:1874-1881.

Office: (813) 745-8090

BACK TO RESEARCH PAGE
 
TOOLS:   Font Size
 |  Site Map  |  Privacy Policy  |  Terms and Conditions  |  Staff Login